MASCT by Hengrui Yuanzheng Biotechnology for Soft Tissue Sarcoma: Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Soft Tissue Sarcoma.

Michigan Cannabis Sales Stall in August

Michigan cannabis sales were unchanged in August from July, down just slightly from the record of $276.7 million to $276.3 million. The growth of 32.9% from

September 14, 2023

Endometriosis linked to increased risk of heart attack and stroke in women

According to research presented at ESC Congress 2024,1 women with endometriosis have a 20% greater risk of significant cardiac outcomes compared with women without endometriosis.

August 29, 2024

More than 1 in 5 Canadians lack access to primary care, research finds

More than 1 in 5 adults in Canada did not have access to primary care, with large regional gaps in access, found new research in

May 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.